{"id":"W4403410305","doi":"10.1016/j.jtho.2024.09.178","title":"MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"National Taiwan University; National Taiwan University Hospital; Saint Petersburg State University; University of Ulsan; Seoul National University Hospital; Moffitt Cancer Center; Seoul National University; Ankara Yıldırım Beyazıt Üniversitesi; McGill University","keywords":"Medicine; Pembrolizumab; Olaparib; Oncology; Internal medicine; Maintenance therapy; Cancer; Immunotherapy; Chemotherapy; Poly ADP ribose polymerase; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001355224,0.001528562,0.002511741,0.0004006371,0.0004632986,0.001730472,0.001026025,0.001122748,0.005458045],"category_scores_gemma":[0.000690704,0.0006544343,0.002156371,0.0003980514,0.000873676,0.001391845,0.0004052522,0.004881899,0.001811086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001456197,"about_ca_system_score_gemma":0.001865081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001584465,"about_ca_topic_score_gemma":0.005240208,"domain_scores_codex":[0.9996828,0.0001028905,0.00001380521,0.00006082876,0.00003412422,0.0001055627],"domain_scores_gemma":[0.9995845,0.00005868558,0.00006675026,0.00003802753,0.00003157362,0.0002204683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6069019,0.06991176,0.00634648,0.002792064,0.005058066,0.0002514399,0.000420765,0.006018356,0.03368528,0.001090255,0.01513329,0.2523903],"study_design_scores_gemma":[0.5677407,0.4011204,0.01405239,0.0001548675,0.001817816,0.0003863218,0.0001537708,0.002493279,0.003427895,0.000611747,0.007967899,0.00007279291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791756,0.00807921,0.0007544788,0.00133572,0.0005455114,0.002675658,0.00234463,0.000221733,0.004867539],"genre_scores_gemma":[0.9705903,0.008079593,0.00207367,0.002492682,0.0003049666,0.002792073,0.004102907,0.00008049314,0.00948323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005458045,"threshold_uncertainty_score":0.01825905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06445639390388534,"score_gpt":0.4905115520562648,"score_spread":0.4260551581523795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}